Safety Study of GNbAC1 in Multiple Sclerosis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.

Scientific research has shown that the expression of genes of a virus which is integrated in the Human genetic material, the Multiple Sclerosis associated RetroVirus (MSRV) could play a critical role in the causation of multiple sclerosis.

GNbAC1 is an experimental medication, which neutralizes (i.e. inactivates) a protein of MSRV that might contribute to the development or deterioration of multiple sclerosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers

NCT02452996

Healthy Volunteers

COMPLETED PHASE1

First-in-Human Study With GNbAC1 in Healthy Volunteers

NCT01699555

Multiple Sclerosis

COMPLETED PHASE1

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

NCT03239860

Multiple Sclerosis, Relapsing-Remitting

TERMINATED PHASE2

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

NCT02782858

Multiple Sclerosis, Relapsing-Remitting

COMPLETED PHASE2

Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers

NCT03574428

Multiple Sclerosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GNbAC1

Group Type EXPERIMENTAL

GNbAC1

Intervention Type BIOLOGICAL

Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg

GNbAC1 placebo

Group Type PLACEBO_COMPARATOR

GNbAC1 placebo

Intervention Type BIOLOGICAL

Single dose intravenous (IV) GNbAC1 placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GNbAC1

Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg

Intervention Type BIOLOGICAL

GNbAC1 placebo

Single dose intravenous (IV) GNbAC1 placebo

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients (if female, neither pregnant nor breast-feeding, should be post-menopausal or surgically sterile, or should use two highly effective method of contraception such as oral contraception plus mechanical barrier); Male subjects with partners of childbearing potential have to use adequate contraception during the study. Contraception methods should be followed during the study and up to 3 months after the last study drug administration. Female subjects who are women of childbearing potential (WOCBP) will have to be tested negative with a pregnancy test (serum or urine) at screening and Day 1 and before each repeated administrations of GNbAC1.
* Between 18 and 65 years of age;
* Patients with Primary Progressive MS (PPMS) according to the Revised McDonald criteria 2010 or patients with Secondary Progressive MS (SPMS) or patients with Relapsing-Remitting MS(RRMS)according to the Revised McDonald criteria 2010 who cannot be treated with available treatments for MS due to intolerance, non response or refusal of treatment;
* Score ≤ 6.5 on the Expanded Disability Status Scale (EDSS);
* Body weight between 40 and 100kg.

Exclusion Criteria

* Positive serology for viral hepatitis and HIV;
* Disease other than MS that could better explain his/her signs and symptoms;
* Previously treated with cladribine, lymphoid irradiation or depleting antibodies;
* Usage in the last 3 months of interferon beta or glatiramer acetate;
* Any usage in the last 6 months of mitoxantrone, cytotoxic immunosuppressive therapy, natalizumab, fingolimod or immunoglobulin;
* Usage within 30 days prior to baseline of oral or systemic corticosteroids or ACTH;
* Inadequate liver function;
* Severe renal impairment;
* Severe psychiatric disorder;
* Known inability to undergo an MRI scan;
* Having participated in another clinical study within 6 months prior to study baseline except for patients who have participated or who are currently participating in an interventional study without any study drug intake.
* Pregnancy or breastfeeding
* Female subjects considering becoming pregnant during the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No